Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Recruiting now · Phase 2
Conditions studied: Pediatric Acute Lymphoblastic Leukemia
In brief
* Clinical and genetic factors consistent with High risk : Induction → Consolidation 1. BM MRD \< 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3. BM MRD ≥ 0.01% after Consolidation <!-- --> 1. T cell ALL : Change to very high risk regimen 2. Pre-B ALL : IM #1 → Intensification 1. BM MRD \< 0.01% after IM #1 : DI #1 → IM #2 → DI #2 → Maintenance 2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen * Difference in the number of \'interim maintenance(IM)\' and \'delayed intensification(DI)\' is important for chemotherapies based on MRD.
Key facts
- Study ID
- NCT06184009
- Run by
- Jae Wook Lee
- People needed
- 370
- Starts
- 2024-08-10
- Expected to finish
- 2030-12-31
- Last updated by the study team
- 2026-07-29
Who can join
Age: 1 and older, up to 19. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Pusan National University Yangsan Hospital — Yangsan, South Korea (enrolling)
- Samsung Medical Center — Seoul, Seoul, South Korea (enrolling)
- Ajou University Hospital — Suwon, South Korea (enrolling)
- Seoul National University Hospital — Seoul, Seoul, South Korea (enrolling)
- Severance Hospital — Seoul, South Korea (enrolling)
- Asan Medical Center — Seoul, South Korea (enrolling)
- Seoul saint Mary's Hospital — Seoul, South Korea (enrolling)
- Inha University Hospital — Incheon, South Korea
- Korea University Anam Hospital — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.